- Home
- GOSS vs DRUG Comparison
GOSS vs DRUG Comparison
Compare GOSS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- DRUG
- Stock Information
- Founded
- GOSS 2015
- DRUG 2019
- Country
- GOSS United States
- DRUG United States
- Employees
- GOSS N/A
- DRUG N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- DRUG Pharmaceuticals and Biotechnology
- Sector
- GOSS Health Care
- DRUG Health Care
- Exchange
- GOSS Nasdaq
- DRUG Nasdaq
- Market Cap
- GOSS 212.8M
- DRUG 253.2M
- IPO Year
- GOSS 2019
- DRUG N/A
- Fundamental
- Price
- GOSS $1.18
- DRUG $35.57
- Analyst Decision
- GOSS Strong Buy
- DRUG Strong Buy
- Analyst Count
- GOSS 5
- DRUG 4
- Target Price
- GOSS $9.20
- DRUG $84.33
- AVG Volume (30 Days)
- GOSS 1.5M
- DRUG 37.2K
- Earning Date
- GOSS 03-13-2025
- DRUG 05-16-2025
- Dividend Yield
- GOSS N/A
- DRUG N/A
- EPS Growth
- GOSS N/A
- DRUG N/A
- EPS
- GOSS N/A
- DRUG N/A
- Revenue
- GOSS $114,701,000.00
- DRUG N/A
- Revenue This Year
- GOSS N/A
- DRUG N/A
- Revenue Next Year
- GOSS $154.71
- DRUG N/A
- P/E Ratio
- GOSS N/A
- DRUG N/A
- Revenue Growth
- GOSS N/A
- DRUG N/A
- 52 Week Low
- GOSS $0.50
- DRUG $0.93
- 52 Week High
- GOSS $1.55
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- GOSS 44.39
- DRUG 49.23
- Support Level
- GOSS $1.10
- DRUG $34.00
- Resistance Level
- GOSS $1.48
- DRUG $38.00
- Average True Range (ATR)
- GOSS 0.12
- DRUG 2.30
- MACD
- GOSS -0.02
- DRUG 0.16
- Stochastic Oscillator
- GOSS 22.14
- DRUG 62.33
Stock Price Comparison Chart: GOSS vs DRUG
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.